Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease

World Journal of Gastroenterology

Volumn 17, Issue 27, 2011, Pages 3235-3241

  Mönnikes, Hubert ^a   Heading, Robert C ^b   Schmitt, Holger ^c   Doerfler, Hubert ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Nycomed GmbH ^*

^c Nycomed GmbH   (Germany)

^d Nycomed International Management GmbH   (Swaziland)

Author keywords

Clinical practice; Gastroesophageal reflux disease; Irritable bowel syndrome; Pantoprazole; ReQuest

Indexed keywords

PANTOPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON EROSIVE REFLUX DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; TREATMENT OUTCOME;

EID: 80051510534     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i27.3235     Document Type: Article

References (35)

1. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998; 42: 690-695
2. Kennedy TM, Jones RH, Hungin AP, O'flanagan H, Kelly P. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut 1998; 43: 770-774
3. Smart HL, Nicholson DA, Atkinson M. Gastro-oesophageal reflux in the irritable bowel syndrome. Gut 1986; 27: 1127-1131
4. Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci 2006; 51: 2113-2120
5. Quigley E, Heading R, Monnikes H. Exploring the spectrum of GERD: myths and realities. Ann Gastroenterol 2007; 20: 155-163
6. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005; 7: 264-271
7. Talley NJ. Overlapping abdominal symptoms: why do GERD and IBS often coexist? Drugs Today (Barc) 2006; 42 Suppl B: 3-8
8. Dickman R, Feroze H, Fass R. Gastroesophageal reflux disease and irritable bowel syndrome: a common overlap syndrome. Curr Gastroenterol Rep 2006; 8: 261-265
9. Pimentel M, Rossi F, Chow EJ, Ofman J, Fullerton S, Hassard P, Lin HC. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol 2002; 34: 221-224
10. Gasiorowska A, Poh CH, Fass R. Gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS)--is it one disease or an overlap of two disorders? Dig Dis Sci 2009; 54: 1829-1834
11. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. International validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 891-898
12. Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2007; 75 Suppl 1: 69-78
13. Mönnikes H, Pfaffenberger B, Gatz G, Hein J, Bardhan KD. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion 2007; 75 Suppl 1: 62-68
14. V. ReQuest: new dimensions in the assessment and management of GERD. Drugs Today (Barc) 2005; 41 Suppl B: 7-11
15. Neumann H, Monkemuller K, Kandulski A, Malfertheiner P. Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett's esophagus. Dig Dis 2008; 26: 243-247
16. Winter JW, Heading RC. The nonerosive reflux diseasegastroesophageal reflux disease controversy. Curr Opin Gastroenterol 2008; 24: 509-515
17. Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5: 690-695
18. Mönnikes H, Doerfler H, Schmitt H, Berghoefer P, Heading R. Is the Response of GERD Patients to PPI Therapy Affected By the Presence of IBS-Like Symptoms? Gastroenterology 2008; 134 (Suppl 1): A126
19. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther 2005; 22: 79-94
20. Zimmerman J, Hershcovici T. Bowel symptoms in nonerosive gastroesophageal reflux disease: nature, prevalence, and relation to acid reflux. J Clin Gastroenterol 2008; 42: 261-265
21. Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998; 316: 285
22. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10: 37
23. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180
24. Bardhan KD, Stanghellini V, Armstrong D, Berghöfer P, Gatz G, Mönnikes H. Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 229-237
25. Mönnikes H, Bardhan KD, Stanghellini V, Berghöfer P, Bethke TD, Armstrong D. Evaluation of GERD symptoms during therapy. Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 238-244
26. Stanghellini V, Armstrong D, Mönnikes H, Bardhan KD. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 463-479
27. Armstrong D, Mönnikes H, Bardhan KD, Stanghellini V. The construction of a new evaluative GERD questionnaire - methods and state of the art. Digestion 2004; 70: 71-78
28. Bardhan KD, Berghöfer P. Look--but also listen! ReQuest: an essay on a new validated scale to assess the outcome of GERD treatment. Digestion 2007; 75 Suppl 1: 87-100
29. Franke A, Singer MV, Dumitrascu DL. How general practitioners manage patients with irritable bowel syndrome. Data from a German urban area. Rom J Intern Med 2009; 47: 47-53
30. Bellini M, Tosetti C, Costa F, Biagi S, Stasi C, Del Punta A, Monicelli P, Mumolo MG, Ricchiuti A, Bruzzi P, Marchi S. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis 2005; 37: 934-939
31. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, Lam M, Seguin R. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol 2003; 3: 28
32. Nojkov B, Rubenstein JH, Adlis SA, Shaw MJ, Saad R, Rai J, Weinman B, Chey WD. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 473-482
33. Fass R, Stanghellini V, Monnikes H, Bardhan K, Berghöfer P, Sander P, Armstrong D. Baseline analysis of symptom spectrum in GERD clinical trial patients: results from the ReQuest ™ database. Gastroenterology 2006; 130 (Suppl 2): A629
34. Jung HK, Halder S, McNally M, Locke GR, Schleck CD, Zinsmeister AR, Talley NJ. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007; 26: 453-461
35. Stanghellini V, Armstrong D, Monnikes H, Bardhan KD, Schmitt H, Teutsch I, Berghöfer P, Fass R. Determination of GERD symptom threshold based on ReQuest™ in an international population. Gut 2006; 55 (Suppl V): A62